SCHEMBL10109873

SCHEMBL10109873

CCOC(=O)c1cc(-c2cccc(Cl)c2)c(-c2cccc(Cl)c2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.54
MAPK14 Q16539 1/20 0.53
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 5/20 0.46
ALOX5 P09917 4/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GRM6 O15303 1/20 0.45
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426748 0.90 FNTA (0.47) TRPM8MAPK14KDM4EALDH1A1HPGD
SCHEMBL423837 0.86 TRPM8 (0.53) TRPM8KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL422050 0.86 TRPM8 (0.53) TRPM8KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL6018669 0.82 MAPK14 (0.65) TRPM8MAPK14KDM4EALDH1A1HPGD
SCHEMBL10109878 0.79 MAPK14 (0.46) MAPK14KDM4EALDH1A1HPGDNPC1
SCHEMBL422503 0.79 MAPK14 (0.48) TRPM8MAPK14KDM4EALDH1A1HPGD
SCHEMBL421904 0.77 MAPK14 (0.56) MAPK14KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL426543 0.76 TRPM8 (0.53) TRPM8KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL18974750 0.76 NPC1 (0.68) TRPM8KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL13398492 0.76 ALDH1A1 (0.59) TRPM8KDM4EALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075962-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 TRPM8 3898/4885MAPK14 2294/4885KDM4E 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.